1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Imipenem / Cilastatin / Relebactam Formulation

Manufacturer or supplier's details
Company: MSD
Address: 199 Wenhai North Road
          HEDA, Hangzhou - Zhejiang Province - CHINA 310018
Telephone: 908-740-4000
Emergency telephone number: 86-571-87268110
E-mail address: EHSDATASETWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance: powder
Colour: White to light yellow
Odour: No data available

Causes serious eye irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

GHS Classification

<table>
<thead>
<tr>
<th>Hazard Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serious eye damage/eye irritation</td>
<td>Category 2A</td>
</tr>
<tr>
<td>Respiratory sensitisation</td>
<td>Category 1</td>
</tr>
<tr>
<td>Reproductive toxicity</td>
<td>Category 2</td>
</tr>
<tr>
<td>Specific target organ toxicity - repeated exposure</td>
<td>Category 2</td>
</tr>
<tr>
<td>Short-term (acute) aquatic hazard</td>
<td>Category 1</td>
</tr>
<tr>
<td>Long-term (chronic) aquatic hazard</td>
<td>Category 1</td>
</tr>
</tbody>
</table>

GHS label elements
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Imipenem / Cilastatin / Relebactam Formula-
tion

Version 4.16
Revision Date: 2020/10/10
SDS Number: 67736-00022
Date of last issue: 2020/07/15
Date of first issue: 2015/02/27

Hazard pictograms:

Signal word: Danger

Hazard statements:
H319 Causes serious eye irritation.
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H361d Suspected of damaging the unborn child.
H373 May cause damage to organs through prolonged or re-
peated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements:
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protec-
tion/ face protection.
P284 Wear respiratory protection.

Response:
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice/ at-
tention.
P337 + P313 If eye irritation persists: Get medical advice/ at-
tention.
P391 Collect spillage.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards
Not classified based on available information.

Health hazards
Causes serious eye irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. Suspected of damaging the unborn child. May cause damage to organs through pro-
longed or repeated exposure.
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Imipenem / Cilastatin / Relebactam Formula-
tion

Version 4.16  Revision Date: 2020/10/10  SDS Number: 67736-00022  Date of last issue: 2020/07/15
Date of first issue: 2015/02/27

Environmental hazards
Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilastatin</td>
<td>81129-83-1</td>
<td>&gt;= 30 - &lt; 50</td>
</tr>
<tr>
<td>Imipenem</td>
<td>74431-23-5</td>
<td>&gt;= 30 - &lt; 50</td>
</tr>
<tr>
<td>Relebactam</td>
<td>1174020-13-3</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-
vice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty
of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water
for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Causes serious eye irritation.
May cause allergy or asthma symptoms or breathing difficul-
ties if inhaled.
Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure.
Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airs-dysfunction syndrome).
Contact with dust can cause mechanical irritation or drying of

3 / 20
Imipenem / Cilastatin / Relebactam Formulation

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Imipenem / Cilastatin / Relebactam Formula-
tion

Version 4.16  Revision Date: 2020/10/10  SDS Number: 67736-00022  Date of last issue: 2020/07/15
Date of first issue: 2015/02/27

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Do not get in eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitisers.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

Storage

Conditions for safe storage:
- Keep in properly labelled containers.
- Store locked up.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

Packaging material: Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilastatin</td>
<td>81129-83-1</td>
<td>TWA</td>
<td>5 mg/m3 (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td>Imipenem</td>
<td>74431-23-5</td>
<td>TWA</td>
<td>1000 ug/m3 (OEB 1)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: RSEN
Imipenem / Cilastatin / Relebactam Formula-
tion

Engineering measures
: Use feasible engineering controls to minimize exposure to compound.
  All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment
Respiratory protection
: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  Filter type
  : Particulates type

Eye/face protection
: Wear safety glasses with side shields or goggles.
  If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
  Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection
: Work uniform or laboratory coat.

Hand protection
Material
: Chemical-resistant gloves

Hygiene measures
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
  When using do not eat, drink or smoke.
  Wash contaminated clothing before re-use.
  The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance
: powder

Colour
: White to light yellow

Odour
: No data available

Odour Threshold
: No data available

pH
: No data available

Melting point/freezing point
: No data available

Initial boiling point and boiling range
: No data available

Flash point
: Not applicable
Evaporation rate : Not applicable
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : Not applicable
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : Not applicable
Relative vapour density : Not applicable
Relative density : No data available
Density : No data available
Solubility(ies)
  Water solubility : soluble
Partition coefficient: n-octanol/water : Not applicable
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, dynamic : No data available
  Viscosity, kinematic : Not applicable
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

10. STABILITY AND REACTIVITY
Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions
  May form explosive dust-air mixture during processing, handling or other means.
  Can react with strong oxidizing agents.
Imipenem / Cilastatin / Relebactam Formulation

Version 4.16  Revision Date: 2020/10/10  SDS Number: 67736-00022  Date of last issue: 2020/07/15  Date of first issue: 2015/02/27

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes: Inhalation  Skin contact  Ingestion  Eye contact

Acute toxicity
Not classified based on available information.

Components:
Cilastatin:
Acute oral toxicity: LD50 (Rat): > 10,000 mg/kg  LD50 (Mouse): > 10,000 mg/kg

Imipenem:
Acute oral toxicity: LD50 (Mouse): 10,000 mg/kg
Acute toxicity (other routes of administration): LD50 (Rat): > 2,000 mg/kg  Application Route: Intravenous
   LD50 (Mouse): 1,500 mg/kg  Application Route: Intravenous

Skin corrosion/irritation
Not classified based on available information.

Components:
Cilastatin:
Species: Rabbit  Result: No skin irritation

Relebactam:
Method: EpiDerm  Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.
Imipenem / Cilastatin / Relebactam Formula-
tion

Components:
Cilastatin:
Species: Rabbit
Result: Moderate eye irritation

Relebactam:
Result: No eye irritation
Method: Bovine cornea (BCOP)

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:
Cilastatin:
Exposure routes: Skin contact
Remarks: No data available
: Inhalation
Remarks: No data available

Imipenem:
Remarks: May cause sensitisation of susceptible persons by inhalation of aerosol or dust.
Exposure routes: Skin contact
Remarks: Not classified due to lack of data.

Relebactam:
Test Type: Local lymph node assay (LLNA)
Exposure routes: Dermal
Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:
Cilastatin:
Genotoxicity in vitro: Test Type: Microbial mutagenesis assay (Ames test)
Result: negative

Imipenem:
Imipenem / Cilastatin / Relebactam Formula-
tion

Genotoxicity in vitro:
- Test Type: In vitro mammalian cell gene mutation test
  Test system: Chinese hamster lung cells
  Result: negative
- Test Type: reverse mutation assay
  Result: negative
- Test Type: unscheduled DNA synthesis assay
  Result: negative
- Test Type: Chromosomal aberration
  Result: negative
- Test Type: sister chromatid exchange assay
  Result: negative

Genotoxicity in vivo:
- Test Type: In vivo micronucleus test
  Species: Mouse
  Application Route: Intravenous
  Result: negative

Relebactam:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: Chromosome aberration test in vitro
  Result: negative

Genotoxicity in vivo:
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cyogenetic test, chromosomal analysis)
  Species: Rat
  Application Route: Intraperitoneal injection
  Result: negative

Germ cell mutagenicity - Assessment:
- Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Suspected of damaging the unborn child.

Components:

Cilastatin:
Effects on fertility:
- Test Type: Fertility/early embryonic development
  Application Route: Intravenous
  Fertility: LOAEL: 1,000
  Symptoms: No adverse effects
  Result: No effects on fertility and early embryonic development were detected.
Imipenem / Cilastatin / Relebactam Formula-
tion

Effects on fertility

**Imipenem:**

**Effects on fertility:**

Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Application Route: Intravenous  
Fertility: LOAEL: 80 mg/kg body weight  
Symptoms: No adverse effects, Reduced foetal weight  
Result: No effects on fertility and early embryonic development were detected.

Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Application Route: Subcutaneous  
Fertility: LOAEL: 320 mg/kg body weight  
Symptoms: No adverse effects, Reduced foetal weight  
Result: No effects on fertility and early embryonic development were detected.

Effects on foetal development

**Effects on foetal development:**

Test Type: Development  
Species: Monkey  
Application Route: Intravenous  
Developmental Toxicity: LOAEL: 100 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects

Test Type: Development  
Species: Rabbit  
Application Route: Intravenous  
Developmental Toxicity: NOAEL: 60 mg/kg body weight  
Result: No teratogenic effects

Test Type: Development  
Species: Rat  
Application Route: Intravenous  
Developmental Toxicity: NOAEL: 60 mg/kg body weight  
Result: No teratogenic effects

Reproductive toxicity - Assessment

**Reproductive toxicity - Assessment:**  
Some evidence of adverse effects on development, based on animal experiments.

Relebactam:

Effects on fertility

**Effects on fertility:**

Test Type: Pre-/postnatal development  
Species: Rat  
Application Route: Subcutaneous  
Fertility: NOAEL: 450 mg/kg body weight

Effects on foetal development

**Effects on foetal development:**

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal injection  
Embryo-foetal toxicity: NOAEL: 450 mg/kg body weight  
Result: No effects on foetal development
### SAFETY DATA SHEET

**according to GB/T 16483 and GB/T 17519**

**Imipenem / Cilastatin / Relebactam Formula-**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.16</td>
<td>2020/10/10</td>
<td>67736-00022</td>
<td>2020/07/15</td>
<td>2015/02/27</td>
</tr>
</tbody>
</table>

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Intraperitoneal injection  
Embryo-foetal toxicity: NOAEL: 450 mg/kg body weight  
Result: No effects on foetal development

Test Type: Development  
Species: Rat  
Application Route: Intravenous  
Developmental Toxicity: NOAEL: \(>= 450\) mg/kg body weight  
Result: No effects on fertility and early embryonic development were detected.

Test Type: Development  
Species: Rabbit  
Application Route: Intravenous  
Developmental Toxicity: NOAEL: 450 mg/kg body weight  
Result: No effects on foetal development

**STOT - single exposure**  
Not classified based on available information.

**STOT - repeated exposure**  
May cause damage to organs through prolonged or repeated exposure.

**Components:**

**Relebactam:**  
Target Organs: Kidney  
Assessment: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**Cilastatin:**  
Species: Rat  
NOAEL: \(>= 500\) mg/kg  
Application Route: Intravenous  
Exposure time: 90 Days  
Remarks: No significant adverse effects were reported

Species: Monkey  
NOAEL: \(>= 500\) mg/kg  
Application Route: Intravenous  
Exposure time: 5 Weeks  
Remarks: No significant adverse effects were reported

**Imipenem:**  
Species: Monkey
**Imipenem / Cilastatin / Relebactam Formula-**

tion

<table>
<thead>
<tr>
<th></th>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4.16</td>
<td>2020/10/10</td>
<td>67736-00022</td>
<td>2020/07/15</td>
<td>2015/02/27</td>
</tr>
</tbody>
</table>

- **NOAEL**: 60 mg/kg
- **LOAEL**: 150 mg/kg
- **Application Route**: Intravenous
- **Exposure time**: 6 Months
- **Target Organs**: Kidney

**Species**: Monkey

<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>120 mg/kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOAEL</td>
<td>150 mg/kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Application Route**: Subcutaneous
| **Exposure time**: 6 Months
| **Remarks**: No significant adverse effects were reported

**Species**: Rat

<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>180 mg/kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Application Route**: Intravenous
| **Exposure time**: 6 Months
| **Remarks**: No significant adverse effects were reported

**Species**: Rabbit

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOAEL</td>
<td>150 mg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Application Route**: Intravenous
| **Exposure time**: 6 Months
| Target Organs: Kidney

**Relebactam**:

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Rat, female</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>150 mg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Application Route**: Intravenous
| **Exposure time**: 30 d

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Rat, male</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>450 mg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Application Route**: Intravenous
| **Exposure time**: 30 d

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Monkey</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>25 mg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Application Route**: Intravenous
| **Exposure time**: 30 d
| **Target Organs**: Kidney

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Monkey</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>37.5 mg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Application Route**: Intravenous
| **Exposure time**: 30 d

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Monkey</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>50 mg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOAEL</td>
<td>150 mg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Application Route**: Intravenous
| **Exposure time**: 3 Months
| **Target Organs**: Kidney
**Imipenem / Cilastatin / Relebactam Formula-**

**SAFETY DATA SHEET**

according to GB/T 16483 and GB/T 17519

---

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure**

**Components:**

**Imipenem:**
- **Inhalation**
  - **Symptoms:** Nausea, Vomiting, Diarrhoea, Fever, hypotension, Dizziness, Drowsiness, Convulsions, pruritis, Rash
  - **Remarks:** May cause sensitisation of susceptible persons by inhalation of aerosol or dust.

**Relebactam:**
- **Skin contact**
  - **Symptoms:** Pain, Discomfort, Diarrhoea, Abdominal pain, insomnia, Nausea, sore throat, Vertigo

---

**12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

**Components:**

**Cilastatin:**
- **Toxicity to fish**
  - **LC50 (Pimephales promelas (fathead minnow)):** > 111 mg/l
  - **Exposure time:** 96 h
  - **Method:** OECD Test Guideline 203

- **Toxicity to daphnia and other aquatic invertebrates**
  - **EC50 (Daphnia magna (Water flea)):** > 99 mg/l
  - **Exposure time:** 48 h
  - **Method:** OECD Test Guideline 202

- **Toxicity to algae/aquatic plants**
  - **EC50 (Anabaena flos-aquae):** > 99 mg/l
  - **Exposure time:** 72 h
  - **Method:** OECD Test Guideline 201

- **EC50 (Pseudokirchneriella subcapitata (green algae)):** > 99 mg/l
  - **Exposure time:** 72 h
  - **Method:** OECD Test Guideline 201

- **NOEC (Anabaena flos-aquae):** 99 mg/l
  - **Exposure time:** 72 h
  - **Method:** OECD Test Guideline 201

- **NOEC (Pseudokirchneriella subcapitata (green algae)):** 99 mg/l
  - **Exposure time:** 72 h
  - **Method:** OECD Test Guideline 201

**Toxicity to fish (Chronic toxi-**

- **EC10 (Pimephales promelas (fathead minnow)):** > 9.9 mg/l
  - **Exposure time:** 32 d
  - **Method:** OECD Test Guideline 210
## Imipenem / Cilastatin / Relebactam Formulation

<table>
<thead>
<tr>
<th>Property Description</th>
<th>Test Parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)</td>
<td>EC10 (Daphnia magna (Water flea)): &gt; 10 mg/l</td>
</tr>
<tr>
<td></td>
<td>Exposure time: 21 d</td>
</tr>
<tr>
<td></td>
<td>Method: OECD Test Guideline 211</td>
</tr>
<tr>
<td>Toxicity to microorganisms</td>
<td>EC50: &gt; 1,000 mg/l</td>
</tr>
<tr>
<td></td>
<td>Exposure time: 3 h</td>
</tr>
<tr>
<td></td>
<td>Test Type: Respiration inhibition</td>
</tr>
<tr>
<td></td>
<td>Method: OECD Test Guideline 209</td>
</tr>
<tr>
<td>Imipenem:</td>
<td></td>
</tr>
<tr>
<td>Toxicity to daphnia and other aquatic invertebrates</td>
<td>EC50 (Daphnia magna (Water flea)): &gt; 78 mg/l</td>
</tr>
<tr>
<td></td>
<td>Exposure time: 48 h</td>
</tr>
<tr>
<td></td>
<td>Method: OECD Test Guideline 202</td>
</tr>
<tr>
<td>Toxicity to algae/aquatic plants</td>
<td>EC50 (Anabaena flos-aquae (cyanobacterium)): 0.0046 mg/l</td>
</tr>
<tr>
<td></td>
<td>Exposure time: 72 h</td>
</tr>
<tr>
<td></td>
<td>Method: OECD Test Guideline 201</td>
</tr>
<tr>
<td></td>
<td>NOEC (Anabaena flos-aquae (cyanobacterium)): 0.002 mg/l</td>
</tr>
<tr>
<td></td>
<td>Exposure time: 72 h</td>
</tr>
<tr>
<td></td>
<td>Method: OECD Test Guideline 201</td>
</tr>
<tr>
<td></td>
<td>EC50 (Pseudokirchneriella subcapitata (green algae)): &gt; 74 mg/l</td>
</tr>
<tr>
<td></td>
<td>Exposure time: 72 h</td>
</tr>
<tr>
<td></td>
<td>Method: OECD Test Guideline 201</td>
</tr>
<tr>
<td></td>
<td>NOEC (Pseudokirchneriella subcapitata (green algae)): 74 mg/l</td>
</tr>
<tr>
<td></td>
<td>Exposure time: 72 h</td>
</tr>
<tr>
<td></td>
<td>Method: OECD Test Guideline 201</td>
</tr>
<tr>
<td>M-Factor (Acute aquatic toxicity)</td>
<td>100</td>
</tr>
<tr>
<td>Toxicity to fish (Chronic toxicity)</td>
<td>NOEC (Pimephales promelas (fathead minnow)): 9.4 mg/l</td>
</tr>
<tr>
<td></td>
<td>Exposure time: 32 d</td>
</tr>
<tr>
<td></td>
<td>Method: OECD Test Guideline 210</td>
</tr>
<tr>
<td>Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)</td>
<td>NOEC (Daphnia magna (Water flea)): 11 mg/l</td>
</tr>
<tr>
<td></td>
<td>Exposure time: 21 d</td>
</tr>
<tr>
<td></td>
<td>Method: OECD Test Guideline 211</td>
</tr>
<tr>
<td>M-Factor (Chronic aquatic toxicity)</td>
<td>10</td>
</tr>
<tr>
<td>Toxicity to microorganisms</td>
<td>EC50: &gt; 1,000 mg/l</td>
</tr>
<tr>
<td></td>
<td>Exposure time: 3 h</td>
</tr>
<tr>
<td></td>
<td>Test Type: Respiration inhibition</td>
</tr>
<tr>
<td></td>
<td>Method: OECD Test Guideline 209</td>
</tr>
</tbody>
</table>

Relebactam:
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

EC50 (Americamysis): > 100 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants:

- EC50 (Pseudokirchneriella subcapitata (green algae)): 86 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201

- NOEC (Pseudokirchneriella subcapitata (green algae)): 12 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201

- EC50 (Anabaena flos-aquae (cyanobacterium)): > 11 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201

- NOEC (Anabaena flos-aquae (cyanobacterium)): 11 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity):

- NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l
  Exposure time: 32 d
  Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

- NOEC (Daphnia magna (Water flea)): 2.7 mg/l
  Exposure time: 21 d
  Method: OECD Test Guideline 211

Toxicity to microorganisms:

- EC50: > 1,000 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition
  Method: OECD Test Guideline 209

- NOEC: 96.3 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition
  Method: OECD Test Guideline 209

Persistence and degradability

**Components:**

**Cilastatin:**

Biodegradability: Result: Not readily biodegradable.
Biodegradation: 27%
Exposure time: 28 d
Method: OECD Test Guideline 301B
Imipenem / Cilastatin / Relebactam Formulation

Imipenem:
Biodegradability : Result: Not readily biodegradable.
    Biodegradation: 29%
    Exposure time: 28 d
    Method: OECD Test Guideline 301B

Relebactam:
Biodegradability : Result: Not readily biodegradable.
    Biodegradation: 11.3%
    Exposure time: 28 d
    Method: OECD Test Guideline 314

Bioaccumulative potential

Components:
Cilastatin:
Partition coefficient: n-octanol/water : log Pow: -3.53

Imipenem:
Partition coefficient: n-octanol/water : log Pow: < -1

Relebactam:
Partition coefficient: n-octanol/water : log Pow: < -2

Mobility in soil

Components:
Cilastatin:
Distribution among environmental compartments : log Koc: 2.3

Relebactam:
Distribution among environmental compartments : log Koc: 2.3

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.
14. TRANSPORT INFORMATION

**International Regulations**

**UNRTDG**
- **UN number**: UN 3077
- **Proper shipping name**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
- **Class**: 9
- **Packing group**: III
- **Labels**: 9

**IATA-DGR**
- **UN/ID No.**: UN 3077
- **Proper shipping name**: Environmentally hazardous substance, solid, n.o.s. (Imipenem)
- **Class**: 9
- **Packing group**: III
- **Labels**: Miscellaneous
- **Packing instruction (cargo aircraft)**: 956
- **Packing instruction (passenger aircraft)**: 956
- **Environmentally hazardous**: yes

**IMDG-Code**
- **UN number**: UN 3077
- **Proper shipping name**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
- **Class**: 9
- **Packing group**: III
- **Labels**: 9
- **EmS Code**: F-A, S-F
- **Marine pollutant**: yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
- Not applicable for product as supplied.

**National Regulations**

**GB 6944/12268**
- **UN number**: UN 3077
- **Proper shipping name**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
- **Class**: 9
- **Packing group**: III
- **Labels**: 9

**Special precautions for user**
- The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet.
15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:

<table>
<thead>
<tr>
<th>Inventory</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>AICS</td>
<td>not determined</td>
</tr>
<tr>
<td>DSL</td>
<td>not determined</td>
</tr>
<tr>
<td>IECSC</td>
<td>not determined</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Further information

Sources of key data used to compile the Safety Data Sheet:

Date format: yyyy/mm/dd

Full text of other abbreviations

AICS - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardisation; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances;
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Imipenem / Cilastatin / Relebactam Formulation

Version 4.16  Revision Date: 2020/10/10  SDS Number: 67736-00022  Date of last issue: 2020/07/15

Date of first issue: 2015/02/27

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CN / EN